VivoSeq
Other

Sleep Disorder

40

Pipeline Programs↗

4

Active Trials↗

22

Companies Involved↗

Sleep Disorder is a moderately active landscape with 40 programs across 22 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Revance Therapeutics, Inc., Sanofi. 15 therapies are approved with 10 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

0/100

Mech. Concentration

7/100

Completion Rate

83/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 1R

Revance Therapeutics, Inc.

1 program

Phase 1Sanofi logo

Sanofi

2 programs

Phase 2Novo Nordisk logo

Novo Nordisk

1 program

Phase 2UCB logo

UCB

2 programs

Phase 3N

Nobelpharma

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical8

Pantoprazole

Wyeth-Lederle Vaccines

Venlafaxine

Wyeth-Lederle Vaccines

Mometasone Furoate

Novartis

Tesamorelin

Theratechnologies

Stalevo

Orion Corporation, Orion Pharma

Phase 12

Pregabalin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Botulinum Toxin Type a

Revance Therapeutics, Inc.

Phase 25

Zolpidem Tartrate

Sanofi

Sodium Oxybate

Jazz Pharmaceuticals

Liraglutide

Novo Nordisk

AD036

Apnimed

Eplivanserin

Sanofi

Phase 310

Zolpidem

Purdue Pharma LP

Zopiclone

Taisho Pharmaceutical Co., Ltd.

Trazodone

Pragma

Propofol

Fresenius Kabi Oncology Ltd.

Melatonin

Neurim Pharmaceuticals Ltd.

Approved15

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Suvorexant

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Ramelteon

Takeda

Brexpiprazole

Otsuka

Opicapone

Amneal Pharmaceuticals, LLC

Analysis

Modality Breakdown

98%

Small molecule

42 of 43 classified programs — the dominant modality here.

2%ALL OTHERSPeptide12%

Small molecule leads; the ring shows all 43 classified programs, each share of the total. Modality classified for 100% of 44 pipeline programs.

Analysis

Trial Status

37

clinical trials

Completed20 · 54%
Unknown status9 · 24%
Recruiting3 · 8%
Withdrawn3 · 8%
Active, not recruiting1 · 3%
Terminated1 · 3%

Clinical Trials

Trial Activity

37 trials

Clinical Study of Perioperative Sleep Disorders in Cardiac Surgery
Recruiting·NNanjing First Hospital, Nanjing Medical University·Phase 4·NCT06778811·180 enrolled
Impact of Sleep Disorders on Innate Immunity in COVID-19 Patients
Recruiting·PParc Taulí Hospital Universitari·N/A·NCT06341374·50 enrolled
HighCycle Study: Effect of Acetazolamide on Sleep Disordered Breathing in Women Compared to Men
Recruiting·UUniversity of Zurich·Phase 4·NCT06498531·270 enrolled
Yangzheng Compound Mixture in the Treatment of Sleep Disorder in Cancer Patients
Active, not recruiting·SShuGuang Hospital·Phase 4·NCT04641819·1,127 enrolled
Trazodone for Sleep Disorders in Alzheimer's Disease
Completed·—·Phase 3·NCT01142258·40 enrolled
A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease
Completed·UCB logoUCB·Phase 3·NCT00243971
The Study of Spectrum of Sleep Disorders in Cirrhotic Patients and the Efficacy of Zolpidem in Cirrhotic Patients With Insomnia
Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02484963·52 enrolled
Improving Perioperative Sleep Disorders
Completed·—·Phase 1·NCT06512155·215 enrolled
OpicApone Sleep dISorder
Completed·BBial - Portela C S.A.·Phase 4·NCT04986995·22 enrolled
The Treatment of Insomnia Comorbid With Sleep Disordered Breathing Using Armodafinil and/or Cognitive Behavioral Therapy for Insomnia
Completed·UUniversity of Pennsylvania·N/A·NCT02552303·39 enrolled
A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders Idiopathic Parkinson's Disease
Completed·UCB logoUCB·Phase 3·NCT00243945·58 enrolled
Z-Drugs for Sleep Disorders in Alzheimer's Disease
Completed·—·Phase 3·NCT03075241·62 enrolled
Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude
Completed·UUniversity of Zurich·Phase 4·NCT03536507·185 enrolled
Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia
Completed·Sanofi logoSanofi·Phase 2·NCT00313885·205 enrolled
Pharmacological Intervention for Symptomatic Mild Sleep Disordered Breathing
Completed·—·Phase 2·NCT04611750·53 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)